Pfizer's bococizumab data in-line with PCSK9 competitors
This article was originally published in Scrip
Executive Summary
Pfizer reported top-line results from a Phase IIb clinical trial that show the highest twice-monthly dose of bococizumab (RN316) cut bad cholesterol levels almost in half, but the company is playing catch-up with two similarly effective PCSK9 inhibitor developers.